Dopamine and Opioid Neurotransmission in Behavioral Addictions: A Comparative PET Study in Pathological Gambling and Binge Eating
Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implication...
Saved in:
Published in | Neuropsychopharmacology (New York, N.Y.) Vol. 42; no. 5; pp. 1169 - 1177 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Nature Publishing Group
01.04.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implications in understanding its relationship with substance use disorders and underlying mechanisms of therapeutic efficacy. Here, we compare opioid and dopamine function between two behavioral addiction phenotypes: pathological gambling (PG) and binge eating disorder (BED). Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [
C]carfentanil and [
F]fluorodopa positron emission tomography using a high-resolution scanner. Binding potentials relative to non-displaceable binding (BP
) for [
C]carfentanil and influx rate constant (K
) values for [
F]fluorodopa were analyzed with region-of-interest and whole-brain voxel-by-voxel analyses. BED subjects showed widespread reductions in [
C]carfentanil BP
in multiple subcortical and cortical brain regions and in striatal [
F]fluorodopa K
compared with controls. In PG patients, [
C]carfentanil BP
was reduced in the anterior cingulate with no differences in [
F]fluorodopa K
compared with controls. In the nucleus accumbens, a key region involved in reward processing, [
C]Carfentanil BP
was 30-34% lower and [
F]fluorodopa K
was 20% lower in BED compared with PG and controls (p<0.002). BED and PG are thus dissociable as a function of dopaminergic and opioidergic neurotransmission. Compared with PG, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic dopaminergic defects. These findings highlight the heterogeneity underlying the subtypes of addiction and indicate differential mechanisms in the expression of pathological behaviors and responses to treatment. |
---|---|
AbstractList | Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implications in understanding its relationship with substance use disorders and underlying mechanisms of therapeutic efficacy. Here, we compare opioid and dopamine function between two behavioral addiction phenotypes: pathological gambling (PG) and binge eating disorder (BED). Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [
11
C]carfentanil and [
18
F]fluorodopa positron emission tomography using a high-resolution scanner. Binding potentials relative to non-displaceable binding (BP
ND
) for [
11
C]carfentanil and influx rate constant (
K
i
) values for [
18
F]fluorodopa were analyzed with region-of-interest and whole-brain voxel-by-voxel analyses. BED subjects showed widespread reductions in [
11
C]carfentanil BP
ND
in multiple subcortical and cortical brain regions and in striatal [
18
F]fluorodopa
K
i
compared with controls. In PG patients, [
11
C]carfentanil BP
ND
was reduced in the anterior cingulate with no differences in [
18
F]fluorodopa
K
i
compared with controls. In the nucleus accumbens, a key region involved in reward processing, [
11
C]Carfentanil BP
ND
was 30–34% lower and [
18
F]fluorodopa
K
i
was 20% lower in BED compared with PG and controls (
p
<0.002). BED and PG are thus dissociable as a function of dopaminergic and opioidergic neurotransmission. Compared with PG, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic dopaminergic defects. These findings highlight the heterogeneity underlying the subtypes of addiction and indicate differential mechanisms in the expression of pathological behaviors and responses to treatment. Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implications in understanding its relationship with substance use disorders and underlying mechanisms of therapeutic efficacy. Here, we compare opioid and dopamine function between two behavioral addiction phenotypes: pathological gambling (PG) and binge eating disorder (BED). Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [ C]carfentanil and [ F]fluorodopa positron emission tomography using a high-resolution scanner. Binding potentials relative to non-displaceable binding (BP ) for [ C]carfentanil and influx rate constant (K ) values for [ F]fluorodopa were analyzed with region-of-interest and whole-brain voxel-by-voxel analyses. BED subjects showed widespread reductions in [ C]carfentanil BP in multiple subcortical and cortical brain regions and in striatal [ F]fluorodopa K compared with controls. In PG patients, [ C]carfentanil BP was reduced in the anterior cingulate with no differences in [ F]fluorodopa K compared with controls. In the nucleus accumbens, a key region involved in reward processing, [ C]Carfentanil BP was 30-34% lower and [ F]fluorodopa K was 20% lower in BED compared with PG and controls (p<0.002). BED and PG are thus dissociable as a function of dopaminergic and opioidergic neurotransmission. Compared with PG, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic dopaminergic defects. These findings highlight the heterogeneity underlying the subtypes of addiction and indicate differential mechanisms in the expression of pathological behaviors and responses to treatment. Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implications in understanding its relationship with substance use disorders and underlying mechanisms of therapeutic efficacy. Here, we compare opioid and dopamine function between two behavioral addiction phenotypes: pathological gambling (PG) and binge eating disorder (BED). Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [ super(11)C]carfentanil and [ super(18)F]fluorodopa positron emission tomography using a high-resolution scanner. Binding potentials relative to non-displaceable binding (BP sub(ND)) for [ super(11)C]carfentanil and influx rate constant (K sub(i)) values for [ super(18)F]fluorodopa were analyzed with region-of-interest and whole-brain voxel-by-voxel analyses. BED subjects showed widespread reductions in [ super(11)C]carfentanil BP sub(ND) in multiple subcortical and cortical brain regions and in striatal [ super(18)F]fluorodopa K sub(i) compared with controls. In PG patients, [ super(11)C]carfentanil BP sub(ND) was reduced in the anterior cingulate with no differences in [ super(18)F]fluorodopa K sub(i) compared with controls. In the nucleus accumbens, a key region involved in reward processing, [ super(11)C]Carfentanil BP sub(ND) was 30-34% lower and [ super(18)F]fluorodopa K sub(i) was 20% lower in BED compared with PG and controls (p<0.002). BED and PG are thus dissociable as a function of dopaminergic and opioidergic neurotransmission. Compared with PG, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic dopaminergic defects. These findings highlight the heterogeneity underlying the subtypes of addiction and indicate differential mechanisms in the expression of pathological behaviors and responses to treatment. Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implications in understanding its relationship with substance use disorders and underlying mechanisms of therapeutic efficacy. Here, we compare opioid and dopamine function between two behavioral addiction phenotypes: pathological gambling (PG) and binge eating disorder (BED). Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [11 C]carfentanil and [18 F]fluorodopa positron emission tomography using a high-resolution scanner. Binding potentials relative to non-displaceable binding (BPND ) for [11 C]carfentanil and influx rate constant (Ki ) values for [18 F]fluorodopa were analyzed with region-of-interest and whole-brain voxel-by-voxel analyses. BED subjects showed widespread reductions in [11 C]carfentanil BPND in multiple subcortical and cortical brain regions and in striatal [18 F]fluorodopa Ki compared with controls. In PG patients, [11 C]carfentanil BPND was reduced in the anterior cingulate with no differences in [18 F]fluorodopa Ki compared with controls. In the nucleus accumbens, a key region involved in reward processing, [11 C]Carfentanil BPND was 30-34% lower and [18 F]fluorodopa Ki was 20% lower in BED compared with PG and controls (p<0.002). BED and PG are thus dissociable as a function of dopaminergic and opioidergic neurotransmission. Compared with PG, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic dopaminergic defects. These findings highlight the heterogeneity underlying the subtypes of addiction and indicate differential mechanisms in the expression of pathological behaviors and responses to treatment. Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implications in understanding its relationship with substance use disorders and underlying mechanisms of therapeutic efficacy. Here, we compare opioid and dopamine function between two behavioral addiction phenotypes: pathological gambling (PG) and binge eating disorder (BED). Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [11C]carfentanil and [18F]fluorodopa positron emission tomography using a high-resolution scanner. Binding potentials relative to non-displaceable binding (BPND) for [11C]carfentanil and influx rate constant (Ki) values for [18F]fluorodopa were analyzed with region-of-interest and whole-brain voxel-by-voxel analyses. BED subjects showed widespread reductions in [11C]carfentanil BPND in multiple subcortical and cortical brain regions and in striatal [18F]fluorodopa Ki compared with controls. In PG patients, [11C]carfentanil BPND was reduced in the anterior cingulate with no differences in [18F]fluorodopa Ki compared with controls. In the nucleus accumbens, a key region involved in reward processing, [11C]Carfentanil BPND was 30-34% lower and [18F]fluorodopa Ki was 20% lower in BED compared with PG and controls (p<0.002). BED and PG are thus dissociable as a function of dopaminergic and opioidergic neurotransmission. Compared with PG, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic dopaminergic defects. These findings highlight the heterogeneity underlying the subtypes of addiction and indicate differential mechanisms in the expression of pathological behaviors and responses to treatment.Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implications in understanding its relationship with substance use disorders and underlying mechanisms of therapeutic efficacy. Here, we compare opioid and dopamine function between two behavioral addiction phenotypes: pathological gambling (PG) and binge eating disorder (BED). Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [11C]carfentanil and [18F]fluorodopa positron emission tomography using a high-resolution scanner. Binding potentials relative to non-displaceable binding (BPND) for [11C]carfentanil and influx rate constant (Ki) values for [18F]fluorodopa were analyzed with region-of-interest and whole-brain voxel-by-voxel analyses. BED subjects showed widespread reductions in [11C]carfentanil BPND in multiple subcortical and cortical brain regions and in striatal [18F]fluorodopa Ki compared with controls. In PG patients, [11C]carfentanil BPND was reduced in the anterior cingulate with no differences in [18F]fluorodopa Ki compared with controls. In the nucleus accumbens, a key region involved in reward processing, [11C]Carfentanil BPND was 30-34% lower and [18F]fluorodopa Ki was 20% lower in BED compared with PG and controls (p<0.002). BED and PG are thus dissociable as a function of dopaminergic and opioidergic neurotransmission. Compared with PG, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic dopaminergic defects. These findings highlight the heterogeneity underlying the subtypes of addiction and indicate differential mechanisms in the expression of pathological behaviors and responses to treatment. |
Author | Parkkola, Riitta Voon, Valerie Hirvonen, Jussi Majuri, Joonas Arponen, Eveliina Kaasinen, Valtteri Alho, Hannu Lahti, Tuuli Joutsa, Juho Johansson, Jarkko Alakurtti, Kati Forsback, Sarita |
Author_xml | – sequence: 1 givenname: Joonas surname: Majuri fullname: Majuri, Joonas – sequence: 2 givenname: Juho surname: Joutsa fullname: Joutsa, Juho – sequence: 3 givenname: Jarkko surname: Johansson fullname: Johansson, Jarkko – sequence: 4 givenname: Valerie surname: Voon fullname: Voon, Valerie – sequence: 5 givenname: Kati surname: Alakurtti fullname: Alakurtti, Kati – sequence: 6 givenname: Riitta surname: Parkkola fullname: Parkkola, Riitta – sequence: 7 givenname: Tuuli surname: Lahti fullname: Lahti, Tuuli – sequence: 8 givenname: Hannu surname: Alho fullname: Alho, Hannu – sequence: 9 givenname: Jussi surname: Hirvonen fullname: Hirvonen, Jussi – sequence: 10 givenname: Eveliina surname: Arponen fullname: Arponen, Eveliina – sequence: 11 givenname: Sarita surname: Forsback fullname: Forsback, Sarita – sequence: 12 givenname: Valtteri surname: Kaasinen fullname: Kaasinen, Valtteri |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27882998$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkkFv1DAQhS1URLeFG2dkiQsHstixEzscKm2XpSBVtBJF6s2a2N5dV4kd7GSlHvnneGmpoOLAyZb9vZl5M3OEDnzwFqGXlMwpYfKdH4Z5SWg9L-vqCZpRwUlRM359gGZENqygjF0foqOUbgihlajlM3RYCinLppEz9ONDGKB33mLwBl8MLjiDv9gphjGCT71LyQWPncendgs7FyJ0eGGM02N-T-_xAi9DP0CE0e0svlxd4a_jZG73iksYt6ELG6ez5gz6tnN-8yvPab5YvMoav3mOnq6hS_bF_XmMvn1cXS0_FecXZ5-Xi_NCc16NBbQtI0xTzVjNoBXctppQrQlISUz2zltjm8qKtTassdxUQGpoGDPrmhsN7Bid3MUdpra3RlufHXZqiK6HeKsCOPX3j3dbtQk7VbFKkIrmAG_uA8TwfbJpVLk72nYdeBumpKiUVNSESv4fKGdNLYRkGX39CL0JU_S5E5kSgjVVSfbUqz-Lf6j69yAz8PYO0DGkFO36AaFE7fdE5T1R-z1RuVcZLx_h2o2wH2m27rp_i34CbhTDLA |
CODEN | NEROEW |
CitedBy_id | crossref_primary_10_1038_s41386_019_0368_x crossref_primary_10_1038_s41467_018_03848_y crossref_primary_10_1159_000527095 crossref_primary_10_1016_j_neubiorev_2020_11_027 crossref_primary_10_1016_S0985_0562_24_00007_4 crossref_primary_10_1016_j_addbeh_2021_107127 crossref_primary_10_1007_s00259_019_04459_5 crossref_primary_10_1016_j_neuroimage_2020_116922 crossref_primary_10_1016_j_nicl_2023_103315 crossref_primary_10_1007_s10899_021_10100_8 crossref_primary_10_1093_brain_awz010 crossref_primary_10_3390_jpm12101719 crossref_primary_10_1016_j_biopsych_2017_06_010 crossref_primary_10_1016_j_celrep_2023_113630 crossref_primary_10_1111_adb_13264 crossref_primary_10_5817_CP2023_5_6 crossref_primary_10_1038_s41380_018_0230_2 crossref_primary_10_1523_JNEUROSCI_1607_20_2021 crossref_primary_10_3389_fpsyt_2020_559966 crossref_primary_10_1007_s11920_024_01534_z crossref_primary_10_1192_j_eurpsy_2023_2458 crossref_primary_10_1007_s40429_019_00256_0 crossref_primary_10_1016_j_jns_2020_116952 crossref_primary_10_1016_j_isci_2021_102497 crossref_primary_10_1371_journal_pcbi_1008410 crossref_primary_10_3390_ijms24119574 crossref_primary_10_1093_brain_awz007 crossref_primary_10_3389_fnins_2020_597524 crossref_primary_10_1038_s41366_021_00996_y crossref_primary_10_1038_s41531_021_00253_z crossref_primary_10_1097_YCO_0000000000000895 crossref_primary_10_1016_j_pnpbp_2019_109847 crossref_primary_10_1097_PR9_0000000000000769 crossref_primary_10_1016_j_neubiorev_2020_09_034 crossref_primary_10_1016_j_neuroimage_2018_07_069 crossref_primary_10_1038_s41398_021_01559_5 crossref_primary_10_1097_FBP_0000000000000496 crossref_primary_10_1007_s10899_019_09828_1 crossref_primary_10_1007_s40429_019_00240_8 crossref_primary_10_1016_j_pharmthera_2017_08_002 crossref_primary_10_1038_s41598_019_53430_9 crossref_primary_10_1111_adb_12677 crossref_primary_10_3390_molecules27092863 crossref_primary_10_1097_FBP_0000000000000606 crossref_primary_10_1038_s41398_020_0762_5 crossref_primary_10_1038_s41398_024_03088_3 crossref_primary_10_1038_s41583_018_0028_x crossref_primary_10_1007_s11064_017_2336_3 crossref_primary_10_47482_acmr_1608775 crossref_primary_10_1016_j_pscychresns_2018_03_006 crossref_primary_10_1017_S0033291720005450 crossref_primary_10_1186_s40337_022_00531_y crossref_primary_10_1515_revneuro_2018_0037 crossref_primary_10_1097_CXA_0000000000000107 crossref_primary_10_3389_fnmol_2019_00255 crossref_primary_10_1016_j_jpsychores_2025_112047 crossref_primary_10_1002_eat_23776 crossref_primary_10_1016_j_euroneuro_2017_09_007 crossref_primary_10_1016_j_biopsych_2018_04_011 crossref_primary_10_1002_mds_27519 crossref_primary_10_1016_j_molmed_2017_12_004 crossref_primary_10_1177_09593543211021157 crossref_primary_10_1080_10550887_2021_1926881 |
Cites_doi | 10.1016/S0006-3223(01)01079-4 10.1038/mp.2014.58 10.1088/0031-9155/52/5/019 10.1038/mp.2015.153 10.1017/S1092852915000681 10.1006/nimg.1997.0303 10.1038/npp.2015.340 10.1017/S1092852915000668 10.1038/jcbfm.1985.87 10.1523/JNEUROSCI.5447-07.2008 10.1038/npp.2014.87 10.4088/JCP.v69n0511 10.3109/00952990.2010.491884 10.1097/00004728-199801000-00027 10.1016/S0893-133X(97)00089-4 10.1016/j.biopsych.2012.11.020 10.1002/14651858.CD001867.pub3 10.1001/archpsyc.62.9.1015 10.1111/add.12066 10.1001/archpsyc.62.1.57 10.1016/j.coph.2008.12.014 10.1016/j.conb.2014.09.005 10.1038/oby.2011.27 10.1038/mp.2013.163 10.1038/npp.2016.12 10.1016/j.biopsych.2012.10.022 10.1055/s-0032-1331747 10.1001/jamapsychiatry.2014.2162 10.1017/S0033291708002900 10.1016/S0896-6273(02)00569-X 10.1038/mp.2012.154 10.1007/s00259-008-0935-6 10.1097/HRP.0000000000000051 10.1002/jlcr.1599 10.1038/npp.2009.129 10.1016/j.neuroimage.2012.02.006 10.1080/10550490902787007 10.1038/jcbfm.2015.53 10.2967/jnumed.111.095240 10.1016/j.neuroimage.2012.06.067 10.7326/M15-2455 10.1111/add.12946 10.1176/appi.ajp.163.2.303 10.1016/j.neuroimage.2006.01.021 10.1159/000435876 10.1001/archneurol.2010.65 10.1002/eat.22114 10.1038/nrn3104 10.1016/j.pscychresns.2012.04.012 10.1192/bjp.bp.110.078105 |
ContentType | Journal Article |
Copyright | Copyright Nature Publishing Group Apr 2017 Copyright © 2017 American College of Neuropsychopharmacology 2017 American College of Neuropsychopharmacology |
Copyright_xml | – notice: Copyright Nature Publishing Group Apr 2017 – notice: Copyright © 2017 American College of Neuropsychopharmacology 2017 American College of Neuropsychopharmacology |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 88G 8AO 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2M M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM |
DOI | 10.1038/npp.2016.265 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Psychology Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Neurosciences Abstracts ProQuest One Psychology MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Neurobiology of behavioral addictions |
EISSN | 1740-634X |
EndPage | 1177 |
ExternalDocumentID | PMC5357051 4320726611 27882998 10_1038_npp_2016_265 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Wellcome Trust grantid: 093705 – fundername: Medical Research Council grantid: MR/P008747/1 |
GroupedDBID | --- -DZ -Q- 0R~ 29N 2WC 36B 39C 4.4 406 5RE 70F 7X7 88E 8AO 8FI 8FJ 8R4 8R5 AACDK AANZL AASML AATNV AAYXX AAYZH ABAKF ABBRH ABDBE ABFSG ABIVO ABJNI ABLJU ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACMFV ACMJI ACPRK ACRQY ACSTC ACZOJ ADBBV ADFRT AEFQL AEJRE AEMSY AENEX AESKC AEVLU AEXYK AEZWR AFBBN AFDZB AFHIU AFKRA AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AHWEU AIGIU AILAN AIXLP AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF AOIJS ASPBG ATHPR AVWKF AYFIA AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BPHCQ BVXVI CCPQU CITATION CS3 DIK DNIVK DPUIP DWQXO E3Z EBLON EBS EE. EIOEI EJD F5P FDB FDQFY FERAY FIGPU FIZPM FSGXE FYUFA GNUQQ GX1 HCIFZ HMCUK HYE HZ~ IWAJR JSO JZLTJ KQ8 M1P M2M M7P NQJWS O9- OK1 P2P P6G PHGZM PHGZT PQQKQ PROAC PSQYO PSYQQ Q2X RNT RNTTT ROL RPM SNX SNYQT SOHCF SOJ SRMVM SWTZT TAOOD TBHMF TDRGL TR2 UKHRP W2D ZGI --K 1B1 53G 5VS AAEDT AALRI AAQFI AAQXK AAXUO ABMAC ABRTQ ABWVN ACIUM ACRPL ACVFH ADCNI ADMUD ADNMO AEUPX AFPUW AGQPQ CAG CGR COF CUY CVF ECM EIF EMB EMOBN FEDTE FGOYB HVGLF IHE LGEZI LOTEE M41 MK0 NADUK NPM NQ- NXXTH PJZUB PPXIY PQGLB R2- RIG RNS RPZ SEW SSZ SV3 ZKB 3V. 7TK 7XB 8FE 8FH 8FK K9. LK8 PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM |
ID | FETCH-LOGICAL-c445t-abb303c1c3363ab74ebc01cc0a880d2654bde95e7fcd39e4d5a06a933df64dca3 |
IEDL.DBID | 7X7 |
ISSN | 0893-133X 1740-634X |
IngestDate | Thu Aug 21 17:33:22 EDT 2025 Mon Jul 21 11:44:18 EDT 2025 Fri Jul 11 09:55:05 EDT 2025 Fri Jul 25 08:57:00 EDT 2025 Mon Jul 21 06:01:42 EDT 2025 Thu Apr 24 23:06:33 EDT 2025 Tue Jul 01 01:05:33 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c445t-abb303c1c3363ab74ebc01cc0a880d2654bde95e7fcd39e4d5a06a933df64dca3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.nature.com/articles/npp2016265.pdf |
PMID | 27882998 |
PQID | 1877395203 |
PQPubID | 33935 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5357051 proquest_miscellaneous_1881760184 proquest_miscellaneous_1843967783 proquest_journals_1877395203 pubmed_primary_27882998 crossref_primary_10_1038_npp_2016_265 crossref_citationtrail_10_1038_npp_2016_265 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-04-01 |
PublicationDateYYYYMMDD | 2017-04-01 |
PublicationDate_xml | – month: 04 year: 2017 text: 2017-04-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: New York |
PublicationTitle | Neuropsychopharmacology (New York, N.Y.) |
PublicationTitleAlternate | Neuropsychopharmacology |
PublicationYear | 2017 |
Publisher | Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group |
References | YH Yau (BFnpp2016265_CR49) 2015; 23 SL McElroy (BFnpp2016265_CR36) 2015; 72 JC Wu (BFnpp2016265_CR48) 1997; 17 V Voon (BFnpp2016265_CR44) 2015; 20 MA Bloomfield (BFnpp2016265_CR5) 2014; 39 HW de Jong (BFnpp2016265_CR11) 2007; 52 H Ziauddeen (BFnpp2016265_CR50) 2013; 18 JE Grant (BFnpp2016265_CR17) 2010; 197 RN Gunn (BFnpp2016265_CR20) 1997; 6 T Toneatto (BFnpp2016265_CR42) 2009; 18 VC Cambridge (BFnpp2016265_CR9) 2013; 73 JE Grant (BFnpp2016265_CR18) 2006; 163 SH Keller (BFnpp2016265_CR26) 2012; 53 ND Volkow (BFnpp2016265_CR43) 2014; 19 D Weintraub (BFnpp2016265_CR46) 2010; 67 RS Desikan (BFnpp2016265_CR12) 2006; 31 C Blanco (BFnpp2016265_CR4) 2015; 110 HK Karlsson (BFnpp2016265_CR25) 2015; 21 A Badiani (BFnpp2016265_CR2) 2011; 12 C Giuliano (BFnpp2016265_CR15) 2015; 20 J Hirvonen (BFnpp2016265_CR23) 2009; 36 RP Woods (BFnpp2016265_CR47) 1998; 22 J Joutsa (BFnpp2016265_CR24) 2012; 60 GJ Wang (BFnpp2016265_CR45) 2011; 19 J Linnet (BFnpp2016265_CR34) 2012; 204 S Forsback (BFnpp2016265_CR14) 2009; 52 T Kienast (BFnpp2016265_CR29) 2013; 46 CS Patlak (BFnpp2016265_CR38) 1985; 5 Y Li (BFnpp2016265_CR33) 2008; 28 I Boileau (BFnpp2016265_CR6) 2013; 108 SW Kim (BFnpp2016265_CR30) 2001; 49 SN Haber (BFnpp2016265_CR21) 2010; 35 TW Robbins (BFnpp2016265_CR40) 2015; 30 KA Brownley (BFnpp2016265_CR8) 2016; 165 I Boileau (BFnpp2016265_CR7) 2014; 19 JE Grant (BFnpp2016265_CR19) 2010; 36 RC Kessler (BFnpp2016265_CR27) 2013; 73 L Kovanen (BFnpp2016265_CR31) 2016; 22 I Mick (BFnpp2016265_CR37) 2015; 41 B Fischl (BFnpp2016265_CR13) 2002; 33 SL McElroy (BFnpp2016265_CR35) 2013; 46 C Li (BFnpp2016265_CR32) 2016; 41 K Alakurtti (BFnpp2016265_CR1) 2015; 35 A Heinz (BFnpp2016265_CR22) 2005; 62 L Clark (BFnpp2016265_CR10) 2012; 63 RC Kessler (BFnpp2016265_CR28) 2008; 38 KC Berridge (BFnpp2016265_CR3) 2009; 9 MN Potenza (BFnpp2016265_CR39) 2005; 62 JK Zubieta (BFnpp2016265_CR51) 1996; 2 JE Grant (BFnpp2016265_CR16) 2008; 69 BFnpp2016265_CR41 |
References_xml | – volume: 49 start-page: 914 year: 2001 ident: BFnpp2016265_CR30 publication-title: Biol Psychiatry doi: 10.1016/S0006-3223(01)01079-4 – volume: 19 start-page: 1037 year: 2014 ident: BFnpp2016265_CR43 publication-title: Mol Psychiatry doi: 10.1038/mp.2014.58 – volume: 52 start-page: 1505 year: 2007 ident: BFnpp2016265_CR11 publication-title: Phys Med Biol doi: 10.1088/0031-9155/52/5/019 – volume: 21 start-page: 1057 year: 2015 ident: BFnpp2016265_CR25 publication-title: Mol Psychiatry doi: 10.1038/mp.2015.153 – volume: 20 start-page: 566 year: 2015 ident: BFnpp2016265_CR44 publication-title: CNS Spectr doi: 10.1017/S1092852915000681 – volume: 6 start-page: 279 year: 1997 ident: BFnpp2016265_CR20 publication-title: Neuroimage doi: 10.1006/nimg.1997.0303 – volume: 41 start-page: 1742 year: 2015 ident: BFnpp2016265_CR37 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2015.340 – volume: 20 start-page: 537 year: 2015 ident: BFnpp2016265_CR15 publication-title: CNS Spectr doi: 10.1017/S1092852915000668 – volume: 5 start-page: 584 year: 1985 ident: BFnpp2016265_CR38 publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.1985.87 – volume: 28 start-page: 2814 year: 2008 ident: BFnpp2016265_CR33 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.5447-07.2008 – volume: 39 start-page: 2397 year: 2014 ident: BFnpp2016265_CR5 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2014.87 – volume: 69 start-page: 783 year: 2008 ident: BFnpp2016265_CR16 publication-title: J Clin Psychiatry doi: 10.4088/JCP.v69n0511 – volume: 36 start-page: 233 year: 2010 ident: BFnpp2016265_CR19 publication-title: Am J Drug Alcohol Abuse doi: 10.3109/00952990.2010.491884 – volume: 22 start-page: 139 year: 1998 ident: BFnpp2016265_CR47 publication-title: J Comput Assist Tomogr doi: 10.1097/00004728-199801000-00027 – volume: 17 start-page: 402 year: 1997 ident: BFnpp2016265_CR48 publication-title: Neuropsychopharmacology doi: 10.1016/S0893-133X(97)00089-4 – volume: 73 start-page: 904 year: 2013 ident: BFnpp2016265_CR27 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2012.11.020 – ident: BFnpp2016265_CR41 doi: 10.1002/14651858.CD001867.pub3 – volume: 62 start-page: 1015 year: 2005 ident: BFnpp2016265_CR39 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.62.9.1015 – volume: 108 start-page: 953 year: 2013 ident: BFnpp2016265_CR6 publication-title: Addiction doi: 10.1111/add.12066 – volume: 62 start-page: 57 year: 2005 ident: BFnpp2016265_CR22 publication-title: Arch General Psychiatry doi: 10.1001/archpsyc.62.1.57 – volume: 9 start-page: 65 year: 2009 ident: BFnpp2016265_CR3 publication-title: Curr Opin Pharmacol doi: 10.1016/j.coph.2008.12.014 – volume: 30 start-page: 66 year: 2015 ident: BFnpp2016265_CR40 publication-title: Curr Opin Neurobiol doi: 10.1016/j.conb.2014.09.005 – volume: 19 start-page: 1601 year: 2011 ident: BFnpp2016265_CR45 publication-title: Obesity doi: 10.1038/oby.2011.27 – volume: 19 start-page: 1305 year: 2014 ident: BFnpp2016265_CR7 publication-title: Mol Psychiatry doi: 10.1038/mp.2013.163 – volume: 41 start-page: 2122 year: 2016 ident: BFnpp2016265_CR32 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2016.12 – volume: 73 start-page: 887 year: 2013 ident: BFnpp2016265_CR9 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2012.10.022 – volume: 46 start-page: 130 year: 2013 ident: BFnpp2016265_CR29 publication-title: Pharmacopsychiatry doi: 10.1055/s-0032-1331747 – volume: 72 start-page: 235 year: 2015 ident: BFnpp2016265_CR36 publication-title: JAMA Psychiatry doi: 10.1001/jamapsychiatry.2014.2162 – volume: 38 start-page: 1351 year: 2008 ident: BFnpp2016265_CR28 publication-title: Psychol Med doi: 10.1017/S0033291708002900 – volume: 2 start-page: 1225 year: 1996 ident: BFnpp2016265_CR51 publication-title: NatMed – volume: 33 start-page: 341 year: 2002 ident: BFnpp2016265_CR13 publication-title: Neuron doi: 10.1016/S0896-6273(02)00569-X – volume: 18 start-page: 1287 year: 2013 ident: BFnpp2016265_CR50 publication-title: Mol Psychiatry doi: 10.1038/mp.2012.154 – volume: 36 start-page: 275 year: 2009 ident: BFnpp2016265_CR23 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-008-0935-6 – volume: 23 start-page: 134 year: 2015 ident: BFnpp2016265_CR49 publication-title: Harv Rev Psychiatry doi: 10.1097/HRP.0000000000000051 – volume: 52 start-page: 286 year: 2009 ident: BFnpp2016265_CR14 publication-title: J Labelled Combd Rad doi: 10.1002/jlcr.1599 – volume: 35 start-page: 4 year: 2010 ident: BFnpp2016265_CR21 publication-title: Neuropsychopharmacology doi: 10.1038/npp.2009.129 – volume: 60 start-page: 1992 year: 2012 ident: BFnpp2016265_CR24 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2012.02.006 – volume: 18 start-page: 219 year: 2009 ident: BFnpp2016265_CR42 publication-title: Am J Addict doi: 10.1080/10550490902787007 – volume: 35 start-page: 1199 year: 2015 ident: BFnpp2016265_CR1 publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.2015.53 – volume: 53 start-page: 495 year: 2012 ident: BFnpp2016265_CR26 publication-title: J Nucl Med doi: 10.2967/jnumed.111.095240 – volume: 63 start-page: 40 year: 2012 ident: BFnpp2016265_CR10 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2012.06.067 – volume: 165 start-page: 409 year: 2016 ident: BFnpp2016265_CR8 publication-title: Ann Intern Med doi: 10.7326/M15-2455 – volume: 110 start-page: 1340 year: 2015 ident: BFnpp2016265_CR4 publication-title: Addiction doi: 10.1111/add.12946 – volume: 163 start-page: 303 year: 2006 ident: BFnpp2016265_CR18 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.163.2.303 – volume: 31 start-page: 968 year: 2006 ident: BFnpp2016265_CR12 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2006.01.021 – volume: 22 start-page: 70 year: 2016 ident: BFnpp2016265_CR31 publication-title: Eur Addict Res doi: 10.1159/000435876 – volume: 67 start-page: 589 year: 2010 ident: BFnpp2016265_CR46 publication-title: Arch Neurol doi: 10.1001/archneurol.2010.65 – volume: 46 start-page: 239 year: 2013 ident: BFnpp2016265_CR35 publication-title: Int J Eating Disord doi: 10.1002/eat.22114 – volume: 12 start-page: 685 year: 2011 ident: BFnpp2016265_CR2 publication-title: Nat Rev Neurosci doi: 10.1038/nrn3104 – volume: 204 start-page: 55 year: 2012 ident: BFnpp2016265_CR34 publication-title: Psychiatry Res doi: 10.1016/j.pscychresns.2012.04.012 – volume: 197 start-page: 330 year: 2010 ident: BFnpp2016265_CR17 publication-title: Br J Psychiatry doi: 10.1192/bjp.bp.110.078105 |
SSID | ssj0015768 |
Score | 2.483937 |
Snippet | Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1169 |
SubjectTerms | Adult Analgesics, Opioid - administration & dosage Analgesics, Opioid - metabolism Behavior, Addictive - diagnostic imaging Behavior, Addictive - metabolism Binge eating Brain - diagnostic imaging Brain - metabolism Bulimia - diagnostic imaging Bulimia - metabolism Carbon Radioisotopes Dihydroxyphenylalanine - administration & dosage Dihydroxyphenylalanine - analogs & derivatives Dopamine - metabolism Female Fentanyl - administration & dosage Fentanyl - analogs & derivatives Gambling - diagnostic imaging Gambling - metabolism Humans Male Middle Aged Original Positron-Emission Tomography Radiopharmaceuticals |
Title | Dopamine and Opioid Neurotransmission in Behavioral Addictions: A Comparative PET Study in Pathological Gambling and Binge Eating |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27882998 https://www.proquest.com/docview/1877395203 https://www.proquest.com/docview/1843967783 https://www.proquest.com/docview/1881760184 https://pubmed.ncbi.nlm.nih.gov/PMC5357051 |
Volume | 42 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9NADLZgkxAvCDpggTEdEuyFhSW5yyXhBbWjY0LaqFAn9S26XxWRaFpo9tBH_nPsa5puIPYcnxLFd7Y_2_cZ4I1JeGqzSIeCkI5wiQxzE_NQWlmYvJCFUwQULy7l-ZX4MkknbcJt2bZVbmyiN9R2bihHfhLnGdWUkoh_XPwMaWoUVVfbERr3YZeoy6ilK5t0gCumWNpHkQUPEYtN2sb3iOcn9YLIKmP5PiG3ctMl_RNn_t0uecP_nD2GR23gyPprTT-Be67uwV6_RtA8W7Ej5ls5fY68Bw8u2op5D45Ga27q1TEbb69aLY_9io61erUHvz8hfJ7hGqZqy74uqnllmafuaMid4XagvBqrajbobvazvrWVvxix_MD67HTLJM5GwzGjHsUVrRippjOy7LOaaboD798zoKwiGypqvn4KV2fD8el52M5nCI0QaRMqrdEBmthwLrnSmXDaRLExkUKjYPHHCm1dkbpsaiwvnLCpiqQqOLdTKaxR_Bns1PPa7QNDlINIM9KRckbYOFJWpTnNtrQ8s6mYBvBuo6LStOTlNEPjR-mL6DwvUaElKbTE9wbwtpNerEk7_iN3sNF22R7dZbndaAG87h7jX6ZKiqrd_JpkMI4j6r07ZfKYGo5yEcDz9QbqPibJENgg0A0gu7W1OgEi_b79pK6-e_LvlKcZGtIXd3_6S3iYUPzhW4wOYKf5de1eYfTU6EN_RA5hdzC8HH37Aw_yHZs |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTgJeEHR8FAYYie2FhSWx84WEULt1dGwt1dRJfQuO7YpKNC20E8oj_xB_I3dumm4g9rZnnxMrdznfz3f-HcBr5fNAR27mCEI6wvihEyuPO6EOExUnYWIkAcVuL-yci0_DYLgBv1d3YaiscuUTraPWU0Vn5PteHFFOyXf5h9l3h7pGUXZ11UJjaRYnpviJkG3-_vgQ9bvj-0ftwUHHKbsKOEqIYOHILEO3rTzFechlFgmTKddTypVoytoPA5FpkwQmGinNEyN0IN1QIu7Xo1BoJTk-9xZsCo5QpgabrXavf1blLSh6t3Frwh1Ef8Oy1N7l8X4-I3pML3zr00Z2eRP8J7L9u0Dz0o53dB_ulaEqay5t6wFsmLwOW80cYfqkYLvMFo_aU_k63O6WOfo67PaXbNjFHhusL3fN9-yMiie72IJfhwjYJziHyVyzz7PxdKyZJQtZ0AaKBkgneWycs1bFJcCaWo_tVYz5O9ZkB2vuctZvDxhVRRY0oy8XlVtnH-Uko1v39j0tOsdkbUnl3g_h_EZ09whq-TQ3T4AhrkJs62auNEpoz5VaBjF109Q80oEYNeDNSkWpKunSqWvHt9Sm7XmcokJTUmiK723ATiU9W9KE_Edue6XttHQW83Rt2g14VQ3jV6bcjczN9IJkMHIksr9rZWKPSpxi0YDHSwOqFuNHCKUQWjcgumJalQDRjF8dycdfLd14wIMIXffT65f-Eu50Bt3T9PS4d_IM7voU_dgCp22oLX5cmOcYuy2yF-UPw-DLTf-jfwCVu1wQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NIU28IOj4CAwwEtsLC01iOx9ICHVry8bY6EMn9S04tisq0bTQTqiP_Fv8ddy5abqB2Nuec46j3Pl8P9_5dwCvdMSlSYLCF4R0hI1iP9Uh92MTZzrN4swqAoqnZ_HRufg4kIMN-L26C0NllSuf6By1mWg6I2-GaUI5pSjgzWFVFtFrd99Pv_vUQYoyrat2GksTObGLnwjfZu-O26jr3SjqdvqHR37VYcDXQsi5r4oCXbgONecxV0UibKGDUOtAoVmbKJaiMDaTNhlqwzMrjFRBrDLOzTAWRiuO770FtxMuQ1pjyaAGeyHF8S6CzbiPOHBQFd0HPG2WUyLKDOM3EW1pl7fDf2Lcv0s1L-193XtwtwpaWWtpZfdhw5YN2G6VCNjHC7bHXBmpO59vwNZpla1vwF5vyYu92Gf99TWv2b4bUTNmL7bhVxuh-xjHMFUa9nk6mowMc7Qhc9pK0RTpTI-NSnZQswqwljEjdylj9pa12OGaxZz1On1G9ZELGtFT89rBsw9qXND9ezfPAZ1oso6iwu8HcH4jmnsIm-WktI-BIcJClBsUgbJamDBQRsmU-moanhgphh68Xqko1xVxOvXv-Ja7BD5Pc1RoTgrNcV4Pdmvp6ZIw5D9yOytt55XbmOVrI_fgZf0Y_zJlcVRpJxckgzEk0f5dK5OGVOyUCg8eLQ2o_pgoQVCFINuD5Ipp1QJEOH71STn66ojHJZcJOvEn13_6C9jClZl_Oj47eQp3IgqDXKXTDmzOf1zYZxjEzYvnbrUw-HLTy_MPpAte4A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dopamine+and+Opioid+Neurotransmission+in+Behavioral+Addictions%3A+A+Comparative+PET+Study+in+Pathological+Gambling+and+Binge+Eating&rft.jtitle=Neuropsychopharmacology+%28New+York%2C+N.Y.%29&rft.au=Majuri%2C+Joonas&rft.au=Joutsa%2C+Juho&rft.au=Johansson%2C+Jarkko&rft.au=Voon%2C+Valerie&rft.date=2017-04-01&rft.pub=Nature+Publishing+Group&rft.issn=0893-133X&rft.eissn=1740-634X&rft.volume=42&rft.issue=5&rft.spage=1169&rft_id=info:doi/10.1038%2Fnpp.2016.265&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=4320726611 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0893-133X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0893-133X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0893-133X&client=summon |